The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy

Journal of Urology

Volumn 170, Issue 5, 2003, Pages 1872-1876

  Ward, John F ^b   Blute, Michael L ^b   Slezak, Jeffrey ^a   Bergstralh, Erik J ^a   Zincke, Horst ^b  

^a MAYO CLINIC   (United States)

^b Gonda 7 ^*

Author keywords

Disease progression; Follow up studies; Prostate specific antigen; Prostatectomy; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; DISEASE COURSE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0141919737     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000091876.13656.2e     Document Type: Article

References (20)

1. Meltzer, D., Egleston, B. and Abdalla, I.: Patterns of prostate cancer treatment by clinical stage and age. Am J Public Health, 91: 126, 2001
2. Han, M., Partin, A. W., Zahurak, M., Piantadosi, S., Epstein, J. I. and Walsh, P. C.: Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol, 169: 517, 2003
3. Hull, G. W., Rabbani, F., Abbas, F., Wheeler, T. M., Kattan, M. W. and Scardino, P. T.: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol, 167: 528, 2002
4. Pound, C. R., Partin, A. W., Eisenberger, M. A., Chan, D. W., Pearson, J. D. and Walsh, P. C.: Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281: 1591, 1999
5. Gerber, G. S., Thisted, R. A., Scardino, P. T., Frohmuller, H. G., Schroeder, F. H., Paulson, D. F. et al: Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA, 276: 615, 1996
6. Catalona, W. J. and Smith, D. S.: Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol, 160: 2428, 1998
7. Trapasso, J. G., deKernion, J. B., Smith, R. B. and Dorey, F.: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol, 152: 1821, 1994
8. Zincke, H., Oesterling, J. E., Blute, M. L., Bergstralh, E. J., Myers, R. P. and Barrett, D. M.: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol, 152: 1850, 1994
9. Patel, A., Dorey, F., Franklin, J. and deKernion, J. B.: Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol, 158: 1441, 1997
10. Roberts, S. G., Blute, M. L., Bergstralh, E. J., Slezak, J. M. and Zincke, H.: PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc, 76: 576, 2001
11. Amling, C. L., Blute, M. L., Bergstralh, E. J., Seay, T. M., Slezak, J. and Zincke, H.: Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol, 164: 101, 2000
12. Amling, C. L., Bergstralh, E. J., Blute, M. L., Slezak, J. M. and Zincke, H.: Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol, 165: 1146, 2001
13. Blute, M. L., Bergstralh, E. J., Iocca, A., Scherer, B. and Zincke, H.: Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol, 165: 119, 2001
14. Jagoditsch, M., Lisborg, P. H., Jatzko, G. R., Wette, V., Kropfitsch, G., Denk, H. et al: Long-term prognosis for colon cancer related to consistent radical surgery: multivariate analysis of clinical, surgical, and pathologic variables. World J Surg, 24: 1264, 2000
15. Terzi, A., Pelosi, G., Falezza, G., Lonardoni, A., Pasini, F. and Calabro, F.: Early hilar lung cancer-clinical aspects and long term survival. Identification of a subgroup of stage IA patients with more favorable prognosis. Lung Cancer, 27: 119, 2000
16. Dillioglugil, O., Leibman, B. D., Kattan, M. W., Seale-Hawkins, C., Wheeler, T. M. and Scardino, P. T.: Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology, 50: 93, 1997
17. Pound, C. R., Partin, A. W., Epstein, J. I. and Walsh, P. C.: Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am, 24: 395, 1997
18. Lange, P. H., Ercole, C. J., Lightner, D. J., Fraley, E. E. and Vessella, R.: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol, 141: 873, 1989
19. Pruthi, R. S., Johnstone, I., Tu, I. P. and Stamey, T. A.: Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer. Urology, 49: 737, 1997
20. Moyad, M. A.: Alternative therapies for advanced prostate cancer. What should I tell my patients? Urol Clin North Am, 26: 413, 1999